COMMUNIQUÉS West-GlobeNewswire

Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017
04/12/2017
OXFORD, United Kingdom, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ: SMMT ), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and [...]
GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress
04/12/2017
- Epidiolex ® (cannabidiol) NDA Submitted to FDA - - Conference call today at 7:30 a.m. EST - LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (GW, the Company or the [...]
Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
04/12/2017
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV ), a clinical stage biopharmaceutical company engaged in the research and development of novel anti- [...]
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
04/12/2017
– 94 Percent of All Pediatric Patients Remain on Larotrectinib or Received Surgery with Curative Intent – – Larotrectinib Demonstrates Central Nervous System Activity with First-Ever TRK Fusion Glioblastoma Response [...]
The promoting mechanism of TRU NIAGEN™ to be featured at the American Academy of Anti-Aging Medicine World Congress
04/12/2017
IRVINE, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today it will feature its [...]
Novo Nordisk A/S - Share repurchase programme
04/12/2017
Bagsværd, Denmark, 4 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Saniona AB: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching
04/12/2017
PRESS RELEASE December 4, 2017 Saniona, a leading biotech company in the field of ion channels, today announces the selection of a preclinical candidate, SAN711, for the treatment of neuropathic pain and chronic itching [...]
Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2018
04/12/2017
Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2018 Herantis Pharma Plc. Company release 4 December 2017 at 9:00 am Herantis Pharma Plc ("Herantis") will publish its Financial [...]
Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
04/12/2017
PARIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today announces the approval [...]
ALK launches ambitious, transformational growth strategy
04/12/2017
Copenhagen, 2017-12-04 07:30 CET (GLOBE NEWSWIRE) -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): Three-year investment plan to extend ALK's leadership in allergy immunotherapy and establish a wider global presence in [...]
Olainfarm will hold Third Quarter 2017 Investor Conference Webinar
04/12/2017
Olaine, 2017-12-04 07:27 CET (GLOBE NEWSWIRE) -- Webinar will be hosted by the Member of the Management Board Salvis Lapiņš. The presentation will be held in English. During the webinar Salvis Lapiņš will inform about [...]
Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
04/12/2017
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec First head-to-head randomized clinical trial comparing the efficacy and safety [...]
L'insuline glargine Toujeo® de Sanofi atteint l'objectif principal d'une étude comparative directe avec l'insuline dégludec
04/12/2017
Communiqué de presse Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) L'insuline glargine Toujeo ® de Sanofi atteint l'objectif principal d'une étude comparative directe avec l'insuline dégludec Premier essai clinique [...]
Lundbeck’s Brintellix approved in China
04/12/2017
Valby, 2017-12-04 07:00 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) will now further enhance its leading position within treatments for Major Depressive Disorder (depression) in China as its newest anti- [...]
Cannabis Wheaton Income Corp. Awarded Startup of the Year at 2017 Canadian Cannabis Awards
04/12/2017
VANCOUVER, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX.V:CBW) (" Wheaton Income " or the " Company ") is pleased to announce that it was awarded Startup [...]
Medigus Announces Distribution Agreement with Micro-Tech Europe for the MUSE™ System in Germany
04/12/2017
OMER, Israel, Dec. 03, 2017 (GLOBE NEWSWIRE) -- OMER, Israel - December 3, 2017 – Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in [...]
Telix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc.
03/12/2017
MELBOURNE, Australia and INDIANAPOLIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic [...]
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
03/12/2017
- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – - Data Help Clarify Protocol Design for Planned ZYN002 Phase 2 [...]
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
03/12/2017
- Phase 1 Clinical Trials of TAK-935/OV935 Demonstrated a Strong Safety Profile and Well Characterized Pharmacokinetic Profile, Supporting Further Clinical Advancement - - Results Support Plasma 24S-hydroxycholesterol [...]

Pages